Drug intelligence / Profile preview

hexamethonium

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral, Intravenous, Subcutaneous
01

Overview

Hexamethonium is a small molecule, quaternary ammonium compound that acts as a non-depolarizing ganglionic blocker and prototypical nicotinic cholinergic antagonist. It selectively blocks neuronal nicotinic acetylcholine receptors (nAChRs) at autonomic ganglia by binding primarily within or on the ion channel pore of the receptor, rather than at the acetylcholine binding site. This results in inhibition of both sympathetic and parasympathetic nervous system transmission at preganglionic sites. Hexamethonium does not affect muscarinic acetylcholine receptors or skeletal neuromuscular junctions. Historically, it was used to treat hypertension but has been replaced by more specific agents due to its broad autonomic effects and side effect profile; it is now mainly used as a research tool[1][2][3][5].

Other names
HexoniumhexamethonehexathonideHexamethonumN,N,N,N',N',N'-hexamethylhexane-1,6-diaminium
02

Targets

CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)Nicotinic Acetylcholine ReceptorCHRM3 (M3)

Beyond the preview

Go deeper on hexamethonium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hexamethonium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call